Heart failure (HF) is a rapidly increasing disease worldwide but there is no global HF study that documents demographics, socioeconomic and clinical factors, diagnostic and management patterns, etiology, biomarkers, co-morbidities, treatments, quality of life, barriers to care and outcomes in all parts of the world. Such knowledge is essential in the prevention and treatment of this global disease.

The primary event outcome of the study will be mortality, by cause. Secondary event outcomes will include non-fatal major events (both resulting in and not resulting in hospitalization).

The G-CHF study will obtain baseline data on participants, from North America, South America, Europe, Africa, Asia and the Middle East, on demographic and socioeconomic data, clinical and laboratory variables, echocardiography, HF etiology, medication use, management patterns, quality of life, barriers to care and health systems. Six-month, 12-month, 18-month and 24-month follow-up data will be obtained to determine changes in management, and patient outcomes.

A sub-study of approximately 4000-5000 patients to measure frailty, cognitive and lung function, mental health, medication adherence, patient-reported barriers to care, dietary assessment, and collection of blood samples for central analysis will additionally be performed.

G-CHF includes risk prediction of heart failure using an integrated genomic-proteomic approach, led by PHRI Senior Scientist, Gui Pare who is also Director of the Genetic and Molecular Epidemiology Laboratory at PHRI/McMaster.

JAMA podcast interview with Philip Joseph on G-CHF results published May 16, 2023.

ESC 2023 G-CHF frailty (PDF) QoL in HF patients 2021 (PDF)
Study Type

Observational - registry

Study Design

Prospective global registry

NO. of Countries


NO. of Sites


NO. of Participants


Study Period

2016 - 2023




Canadian Institutes of Health Research (CIHR)

Back To Top